Physician profile
Benjamin T Klausing
NPI 1851618102
$6,546.86
in general payments reported to CMS, 2019-2025
14 companies · $172 in 2025
The $172 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,274 · 2020: $12.70 · 2022: $17.74 · 2023: $18.17 · 2024: $52.14 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $242.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tetraphase Pharmaceuticals, INC. | $5,765.53 | 2019 | |
| Astellas Pharma US INC | $164.47 | 2019 | |
| Insmed, INC. | $141.22 | 2019 | |
| Phathom Pharmaceuticals, INC. | $119.70 | 2025 | Voquezna |
| Gilead Sciences, INC. | $110.72 | 2019-2025 | |
| Viiv Healthcare Company | $78.63 | 2019 | |
| Merck Sharp & Dohme LLC | $66.37 | 2020-2025 | Pifeltro, Delstrigo |
| Aimmune Therapeutics, INC. | $18.17 | 2023 | |
| Dynavax Technologies Corporation | $17.63 | 2025 | Heplisav-B |
| Melinta Therapeutics, LLC | $17.07 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $12.34 | 2019 | |
| Janssen Biotech, INC. | $12.27 | 2019 | |
| Allergan, INC. | $11.60 | 2019 | |
| Mayne Pharma Commercial LLC | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Klausing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.